Comprehensive and long-term surveys of COVID-19 sequelae in Japan, an ambidirectional multicentre cohort study: study protocol


ABSTRACT

Introduction The rapid spread of COVID-19 posed a global burden. Substantial number of people died of the disease in the acute phase of infection. In addition, a significant proportion of patients have been reported to suffer from post-acute phase symptoms, sequelae of COVID-19, which may negatively influence the quality of daily living and socioeconomic circumstances of the patients. However, no previous study has comprehensively and objectively assessed the quality of life of patients by using existing international scales. Further, evidence of socioeconomic consequences among patients with COVID-19 is scarce. To address the multidimensional issues from sequelae of COVID-19, evidence from comprehensive surveys beyond clinical perspectives is critical that investigates health, and social determinants of disease progression as well as socioeconomic consequences at a large scale.

Methods and analysis In this study, we plan to conduct a nationwide and comprehensive survey for the sequelae of COVID-19 in a total of 1000 patients diagnosed at 27 hospitals throughout Japan. This study will evaluate not only the health-related status of patients from clinical perspectives but also the Health-related Quality of Life (HRQoL) scores, socioeconomic status and consequences to discuss the sequelae of the disease and the related risk factors. The primary endpoint is the frequency of long-term complications of COVID-19 infection. The secondary endpoints are risk factors for progression to sequelae of COVID-19 infection. The study will provide robust and important evidence as a resource to tackle the issues from the sequelae of COVID-19 from the multi-dimensional perspectives.

Ethics and dissemination This trial was approved by the Keio University School of Medicine Ethics Committee (20200243, UMIN000042299). The results of this study will be reported at a society meeting or published in a peer-reviewed journal.

INTRODUCTION

In early 2020, an outbreak of SARS-CoV-2 infection also known as COVID-19 spread around the world. In Japan, the outbreak began in March 2020, and by November, the total number of infected people had reached 100,000. The pandemic imposed major...
limitations in the lives of many patients. SARS-CoV-2 infection may cause a wide variety of symptoms, including diarrhoea and olfactory and taste disturbances, in addition to respiratory symptoms such as cough, sore throat and fever. According to the study by the WHO using data from China, the first country in the world to experience a COVID-19 pandemic, mild cases of COVID-19 infection improve in about 2 weeks and severe cases in 3–6 weeks.

However, the sequelae of COVID-19 have been recently attracting attention, and many patients who were discharged from the hospital or returned to their pre-disease lives after recovery of their general condition have been found to show sequelae and have not completely recovered to their pre-disease health. In a study in the USA, 60% of patients complained of some aftereffects at 3 weeks after COVID-19 diagnosis, and in an Italian study, about 90% of patients were still dissatisfied with their health 2 months after the onset of the disease. Many of these patients complained of symptoms such as fatigue, dyspnoea and joint pain for a long time. Some patients have suffered economic and social losses due to physical and mental disabilities that interfere with their work. In a Chinese survey, sequelae were more varied and included alopecia, psychiatric symptoms and cardiovascular-related symptoms, and many patients’ social lives are greatly threatened by these aftereffects. Thus, various sequelae of COVID-19 have been reported globally and are attracting much attention from a clinical perspective and beyond.

Additionally, the previous reports indicated that the incidence of olfactory taste disorder in Asians was around 18% and the incidence of olfactory dysgeusia in Caucasians was higher than in Asians. Therefore, there may be racial differences in the symptoms, frequency and severity of sequelae. In Japan, a study of 78 patients at the National Center for Global Health and Medicine followed the course of various symptoms (fever, cough, fatigue, dyspnoea, dysgeusia, dyssomnias, sputum production and chest pain) after discharge from the hospital by telephone interviews. However, this was a single-centre survey with a small number of patients that focused on clinical symptoms and was limited to urban areas. Thus, there have been no comprehensive, long-term large surveys of the COVID-19 sequelae in Japan. Globally, the occurrence and duration of COVID-19 sequelae are largely unknown, and the long-term complications caused by COVID-19 have not been evaluated.

Besides these significant clinical burdens that patients with COVID-19 carry, existing evidence also suggests the socioeconomic influence of COVID-19 against these patients.

For example, the severity and mortality of COVID-19 are known to vary with comorbidity and age, but the incidence and duration of sequelae may vary in each case. In addition, COVID-19 mortality is reported to be affected by the economic status of the region where the disease occurs. The incidence and duration of the clinical sequelae of COVID-19 may finally vary by socioeconomic circumstance, and the sequelae may have distinct socioeconomic consequences among these patients. Yet, few studies have evaluated the association between social background, economic status, health-related quality of life and sequelae in patients with COVID-19 to understand the socioeconomic impact of COVID-19 on the patients’ life.

This study is a comprehensive multicentre survey of Japanese patients with COVID-19 that used a questionnaire to investigate the occurrence of sequelae, quality of life (QoL) and socioeconomic changes after the onset of COVID-19, and evaluated the long-term impact of the COVID-19 pandemic on Japanese patients as well as on Japanese society. All hospitalised patients with COVID-19 at the participating hospitals throughout Japan including both community hospitals and university hospitals are included in the survey, which reduces selection bias and allows for accurate assessment of the prevalence of each symptom. By comparing the results of this study with those of other studies conducted abroad, we can compare the differences in the occurrence of sequelae between races and populations. This study also allows comparison of the severity at the acute phase and the occurrence of sequelae at the chronic phase and evaluation of the correlation. This study also assesses socioeconomic circumstances and consequences among patients with COVID-19 to understand the multidimensional issues from sequelae of COVID-19. Elucidation of the complications and sequelae of COVID-19 in Japan from multidisciplinary perspectives will provide useful information for both patients and society to appropriately confront COVID-19 in the future.

**METHODS AND ANALYSIS**

**Study design**

This study is designed as a multicentre, ambidirectional cohort study (planned to run from November 2020 to March 2022) conducted using existing international quality of life assessment scale and original questionnaires. Approximately 1000 patients from 27 medical facilities will participate in this study in Japan. These participants have been registered from facilities across the country including urban, suburban and rural area. The inclusion criteria are as follows: age over 18 years, agreement to participate this survey, diagnosed with COVID-19 by a SARS-CoV-2 PCR test or an antigen test, admitted to the participating medical centres. The exclusion criteria are age under 18 years or patients with language impairment, cognitive impairment or psychiatric disorders that interfere with understanding of informed consent or reading and answering the questionnaires in this study.

**Study objectives**

The primary objective was to investigate the frequency and duration of long-term COVID-19 sequelae in Japan. The secondary objectives were to (1) identify the risk

---

Reference:
factors for development of sequelae the relevance of sequelae to acute severity of COVID-19, (2) investigate the influence of COVID-19 sequelae on health-related quality of life and mental health, (3) the association of COVID-19 sequelae with socioeconomic circumstances and consequences, and (4) evaluation of rehabilitation for COVID-19 aftereffects.

All of the QoL rating scales are international standards, it will be possible to compare them in various ways with previous studies or studies to be reported in the future.

Research schedule
The participating institutions will send a participant information sheet to the potential participants, informing them about the details of the study and enquiring about their willingness to participate in the study. After the participant’s consent has been obtained, patient information will be registered in the case information registration system, and electronic patient-reported outcome (e-PRO) or paper patient-reported outcome (p-PRO) will be set up. Participants can choose between e-PRO or p-PRO of their own initiative. The principal investigator will inform the research collaborators of the details of the e-PRO setup by a smartphone app or notification of p-PRO by mail, and collect information regarding sequelae at 3, 6 and 12 months after COVID-19 diagnosis by performing a questionnaire survey.

Information on the questionnaire
The questionnaire is divided into two main sections. The first section comprehensively surveys the symptoms that appeared at the time of COVID-19 diagnosis, their duration, timing of appearance, severity and sequelae. This section is the original questionnaire developed by this study team and the symptoms evaluated in this survey are summarised in Table 1. For the duration of each symptom, there are seven periods to choose from less than 1 week, 1 week to 1 month, 1–3 months, 3–6 months, 6–12 months, more than 12 months, and the symptom still persists. In particular, patients with respiratory, visual, olfactory, gustatory and memory disturbances are assessed using a more detailed questionnaire. Responders with sequelae of dyspnoea will be assessed in detail by the Modified Medical Research Council (mMRC) Dyspnea Scale. The additional questionnaire on olfactory and taste disorders will be used, which is developed by American Academy of Otolaryngology-Head and Neck Surgery. Similarly, additional questions regarding memory loss correspond to the Everyday Memory Checklist Japanese edition.

We will also evaluate symptoms that had improved and re-emerged after the onset of COVID-19, as well as new symptoms that appeared after discharge.

In the second part of the questionnaire, the patients’ quality of life will be assessed by international rating scales, including the HRQoL scales and other related tools on socioeconomic aspects. In this survey, we will be using Short Form-8 (SF-8), Euro Quality of Life 5 Dimensions 5 Level (EQ-5D-5L), Hospital Anxiety and Depression Scale (HADS), the Pittsburgh Sleep Quality Index, WHO Health and Work Performance Questionnaire (short form) Japanese edition, Fear of Coronavirus-19 Scale and the Performance status. We will also assess the participants’ socioeconomic circumstances and relevant changes in the COVID-19 pandemic, including the situation of employment, income, social life and informal care, in this section. To evaluate the onset and clinical course of the sequelae, participants will be asked to reflect on their condition on 3, 6 and 12 months after COVID-19 diagnosis.

Table 1 Symptoms assessed in the first questionnaire

<table>
<thead>
<tr>
<th>Fever</th>
<th>Cough</th>
<th>Sputum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poor concentration</td>
<td>Fatigue</td>
<td>Alopecia</td>
</tr>
<tr>
<td>Memory impairment</td>
<td>Headache</td>
<td>Sore throat</td>
</tr>
<tr>
<td>Muscular weakness</td>
<td>Unconsciousness</td>
<td>Diarrhoea</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>Numbness</td>
<td>Myalgia</td>
</tr>
<tr>
<td>Eye-related symptoms</td>
<td>Dyspnoea</td>
<td>Arthralgia</td>
</tr>
<tr>
<td>Hypersensitivity to sound, light and smell</td>
<td>Tinnitus</td>
<td>Rash</td>
</tr>
<tr>
<td>Sleeping disorders</td>
<td>Olfactory disorders</td>
<td>Taste disorders</td>
</tr>
</tbody>
</table>

Figure 1 After confirming the research collaborator’s consent to participate and cooperate in this study, basic and clinical information of the research collaborator, such as treatment history, will be registered in the case information registration system, and the electronic patient-reported outcome (e-PRO) or paper patient-reported outcome (p-PRO) will be set up. Participants can choose between e-PRO or p-PRO of their own initiative. The principal investigator will inform the research collaborators of the details of the e-PRO setup by a smartphone app or notification of p-PRO by mail, and collect information regarding sequelae at 3, 6 and 12 months after COVID-19 diagnosis by performing a questionnaire survey.
the onset of COVID-19 infection, and responses will be collected for each point in time.

**Collection of clinical information**

At the time of participant enrolment, the principal investigator will collect clinical information from medical records, including participants’ symptoms and clinical information such as age, sex, comorbidity, physical and clinical examination findings laboratory findings, ECG, radiological findings and clinical course. Subsequently, information on the sequelae of COVID-19 infection will be collected at 3, 6 and 12 months after COVID-19.

<table>
<thead>
<tr>
<th>Table 2 Study calendar</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td><strong>At registration</strong></td>
</tr>
<tr>
<td><strong>3 months after</strong></td>
</tr>
<tr>
<td><strong>diagnosis</strong></td>
</tr>
<tr>
<td><strong>6 months after</strong></td>
</tr>
<tr>
<td><strong>diagnosis</strong></td>
</tr>
<tr>
<td><strong>12 months after</strong></td>
</tr>
<tr>
<td><strong>diagnosis</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participant background</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical history: date of diagnosis, comorbidities, allergies, medications, pregnancy status and route of infection</td>
<td>○</td>
</tr>
<tr>
<td>COVID-19 severity</td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Physical findings</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Height and weight</td>
<td>○</td>
</tr>
<tr>
<td>Vital signs</td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical laboratory data</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical symptoms*</td>
<td>○ ○ ○</td>
</tr>
<tr>
<td>Blood test findings†</td>
<td>○</td>
</tr>
<tr>
<td>ECG</td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Radiological examination</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest radiography</td>
<td>○</td>
</tr>
<tr>
<td>Chest CT scan</td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical course</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment progress and outcomes‡</td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rehabilitation survey</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>e-PRO or p-PRO</td>
<td>○ ○ ○</td>
</tr>
<tr>
<td>SF-8 Standard Ver.</td>
<td>○ ○ ○</td>
</tr>
<tr>
<td>EQ-5D-5L</td>
<td>○ ○ ○</td>
</tr>
</tbody>
</table>

HADS

<table>
<thead>
<tr>
<th>The Pittsburgh Sleep Quality Index</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Fear of Coronavirus-19 Scale</td>
<td>○ ○ ○</td>
</tr>
<tr>
<td>Modified Medical Research Council Dyspnea Scale</td>
<td>○ ○ ○</td>
</tr>
</tbody>
</table>

| Investigation of sequelae and symptoms other than those covered in the above assessments | ○ ○ ○ |

| Questionnaire about economic status | ○ |

* Fever, cough, sputum, sore throat, nasal congestion, dyspnoea, diarrhoea, vomiting, fatigue, olfactory disturbances, taste disorders, etc.
† Red cell count, white cell counts, haemoglobin level, hematocrit, platelet count, total protein, albumin, total bilirubin, AST, ALT, LDH, ALP, BUN, creatinine, Na, K, Cl, Ca, IP; blood sugar, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, ferritin, KL-6, and BNP levels, urinary pneumococcal antigen, urinary Legionella antigen, PCT, etc.
‡ Use of oxygen and ventilators, antibiotics and antivirals, steroids, treatment effects, date of diagnosis, date of admission and discharge, etc.

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, brain natriuretic peptide; BUN, blood urea nitrogen; e-PRO, electronic patient-reported outcome; EQ-5D-5L, Euro Quality of Life 5 Dimensions 5 Level; HADS, Hospital Anxiety and Depression Scale; HbA1c, Hemoglobin A1c; HDL, high-density lipoprotein cholesterol; IP, inorganic phosphorus; LDL, lactate dehydrogenase; LDL, low-density lipoprotein cholesterol; p-PRO, paper patient-reported outcome; SF-8, Short Form-8.
diagnosis with e-PRO or p-PRO (table 2). The participants can choose between e-PRO or p-PRO at the start. From this survey, the specific time of appearance and disappearance of the sequelae, as well as the patient’s background, will be determined to gain an overall understanding of the sequelae of COVID-19 infection in Japan. In addition, using health-related quality of life questionnaires (SF-8, Eq-5D-5L, HADS, the Pittsburgh Sleep Quality Index, WHO Health and Work Performance Questionnaire (short form) Japanese edition, Fear of Coronavirus-19 Scale and mMRC Dyspnea Scale, we will evaluate not only the disability caused by physical sequelae such as respiratory symptoms in daily life but also the psychological anxiety caused by these sequelae. We will also research the economic status of the subjects and assess association with COVID-19 infection. In this study, we do not have a clear protocol for rehabilitation. We will try to question patients about the rehabilitation they received after discharge from the acute care hospital, to the extent possible.

SARS-CoV-2 can be transmitted to others if the virus released in respiratory secretions when an infected person coughs, sneezes or speaks is inhaled or comes in direct contact with mucous membranes. Contact with contaminated materials is also not considered a major route of transmission, but it is possible to become infected if your hands become contaminated with these secretions or if you touch your eyes, nose or mouth after touching a contaminated surface. We believe that the electronic medium, e-PRO, to collect the sequelae information in this study, is also effective in preventing the transmission of SARS-CoV-2 from subjects to researchers. In addition, e-PRO is considered to be an effective data collection method because of its various advantages such as prevention of erroneous entries, speedy collection of questionnaires, abatement of the burden on participants and reduction of the cost to send questionnaires.

All data will be collected by the Data Management Centre at 3H Holdings (Tokyo, Japan). There will be no direct communication between investigators and data managers. The clinical data entry, coding, data management and reporting will be performed using the data management system 3H-P Guardian (3H Holdings).

Sample size calculations and statistical analysis
According to a survey conducted by the National Institute of Infectious Diseases in Japan, as of the end of August 2020, there were approximately 40,000 cases of new coronavirus infection and less than 1000 deaths in Japan. It is reported that about 8000 patients required inpatient treatment for COVID-19, and about 7000 patients were discharged or released from hospital. Based on the current number of patients, we estimate that the number of patients who can be tracked and registered at the research cooperating facilities will be about 30% of the patients who received inpatient treatment, and eventually 1000 patients will be eligible for registration.

For the primary outcomes, summary statistics such as frequency and mean, SD will be described for each sequel. For secondary outcomes, summary statistics will be described for each QoL-related rating scale, clinical findings, laboratory examinations and actual rehabilitation status for each case at each time point. We will also conduct exploratory analysis of various scores by severity of illness using ANOVA and generalised linear models. In addition, factors that predict other sequelae, such as pulmonary dysfunction and decreased QoL, will be explored by multivariate analysis.

Further statistical analyses will be conducted to assess the association of COVID-19 sequelae with socioeconomic circumstances and consequences, employing multivariate analysis and structural equation modelling.

Confidentiality and data retention
Responses collected in this questionnaire will be kept strictly anonymous and confidential and will not be used outside of this study to identify the participants. No participant identifiers will be included in the case report form. Participants will be anonymised in both the e-PRO and p-PRO media using numbers generated by the research facility. The anonymised list will be kept securely locked by the personal information manager. The personal information of the participants will be kept confidential, even in the event of allowing access to the original data of the study or publication in a medical journal. For answers by e-PRO, in addition to the anonymisation number, a different ID and password will be used for login authentication to the server. The password is set individually by the participant, and the e-PRO data on the server do not contain any personal information.

Ethics and dissemination
We have received approval from the research ethics committees of the Keio University School of Medicine, JAPAN, to conduct this study (20200243). All respondents to this study will be accredited only if they have completed the informed consent questions in advance and have indicated their consent for participation in the study. Participation in this study is completely voluntary. In addition, participants will be informed that they are free to withdraw their consent at any time. All participants may choose not to respond to one or more specific questions. The UMIN ID for this survey is 00042299.

Patient and public involvement statement
No patient involved in the development of the research question, study design, recruitment, outcome measures, dissemination plans and conduction of the study.
The study findings will be disseminated through open-access scientific publications, stakeholder networks and national/international meetings.

**DISCUSSION**

This long-term, large, ambidirectional study aims to comprehensively investigate the various sequelae of COVID-19 and more objectively evaluate the QoL by using multiple international rating scales. There is no precedent for a study of the same scale, and the information from this survey will be very meaningful. Only moderate and severe cases of COVID-19 were included in this study, and mild cases without pneumonia were excluded. Therefore, it is not possible to assess the sequelae of mild cases from this study, as these results may be influenced by the severity of the acute phase.

In this study, we do not have a protocol for rehabilitation. However, in some cases, after completing the acute treatment, the patient was transferred to a chronic hospital for rehabilitation owing to a decrease in the Activities of Daily Living (ADL) and the need for oxygen therapy. We will try to investigate each patient’s rehabilitation status—whether they have received rehabilitation programme after discharge from the acute care hospital—via questionnaires.

The first part of the questionnaire investigates the various symptoms listed in table 1, including respiratory, gastrointestinal and skin symptoms. No previous study has conducted such an extensive and long-term follow-up of COVID-19 sequelae. We will learn more about the clinical course of COVID-19 by assessing the reappearance of symptoms after improvement, their duration and the relationship between sequelae and the severity of illnesses, comorbidities and age groups. In particular, the American Academy of Otorhinolaryngology’s International Scale and Everyday Memory Rating Scale are being used to assess olfactory, taste and memory impairments, ensuring external validity and allowing for comparisons between races and nations.

The second part of the questionnaire assesses Japanese patients with COVID-19 from the multidimensional perspectives such as quality of life, mental health and socioeconomic consequences including work performance by using six international standard rating scales, namely, the SF-8, EQ-5D-5L, HADS, the Pittsburgh Sleep Quality Index, the WHO Health and Work Performance Questionnaire (WHO-HPQ) and the Fear of COVID-19 Scale (FVC-19S), as well as additional original questions. No previous study has comprehensively and objectively assessed the quality of life of Japanese patients with COVID-19 by using these international scales or investigated the socioeconomic influence of COVID-19 among the patients. Comparisons of the results obtained with these six scales is expected to yield new insights, especially since no previous study has employed these six scales simultaneously. In addition, all these scales are frequently used internationally, ensuring external validity and allowing comparisons of the results with previous studies.

The risk factors for COVID-19 severity have been actively debated worldwide, and many factors have been elucidated. A previous study evaluated respiratory function tests at hospital discharge in 110 cases of COVID-19 to determine risk factors for sequelae and suggested that disease severity was significantly associated with the degree of diffusion impairment on respiratory function tests. In this nationwide study, we aim to perform more comprehensive and longer-term evaluations of post-discharge sequelae and QoL scores and to analyse risk factors for the appearance of sequelae and deterioration of QoL. This study will help clarify the risk factors for sequelae by comparing the results of questionnaire assessments with the medical record information obtained at the time of hospitalisation.

The mMRC Dyspnea Scale, which will be used as a measure of dyspnoea in this study, is primarily used to assess breathlessness in patients with chronic obstructive pulmonary disease and is highly correlated with other measures of health status, and it can be used to predict relative future risk of death. Patients with COVID-19 have been reported to experience prolonged shortness of breath as sequelae, showing significantly higher mMRC scores than those before hospitalisation, and worsening mMRC is associated with a decline in forced expiratory volume 1.0 (FEV1.0) and diffusing capacity for carbon monoxide (DLCO) in actual respiratory function tests. By using mMRC as a measure of shortness of breath in this study, it was possible to objectively evaluate the relationship between the sequelae of dyspnoea and treatment or severity in the acute phase, and determine whether this symptom had improved or not.

COVID-19 sequelae include not only physical disabilities but also psychological problems such as insomnia and memory impairment. In one study that evaluated the sequelae in 120 patients with COVID-19 4 months after discharge, approximately 30% of the patients complained of insomnia and forgetfulness. In the present study, participants who complain of memory impairment will be additionally assessed with the Everyday Memory Checklist Japanese edition. Although the Japanese version of the Everyday Memory Checklist has never been used for memory disorders in patients with COVID-19, this scale has been reported to be reliable and valid in assessing daily memory problems. In the present study, we believe that the Everyday Memory Checklist can be used for a detailed examination of the extent to which memory impairments as a sequela of COVID-19 affect daily life.

In this study, we have adopted the SF-8 as a measure of patients’ QoL. A previous study used SF-36 to prove that respiratory rehabilitation in patients with COVID-19 improves patients’ respiratory function as well as their quality of life. However, no previous studies have evaluated the quality of life of patients with COVID-19 by SF-8. The SF-8 is classified as a comprehensive scale for assessing HRQoL and allows comparison of between patients with different sequelae in different medical settings.
diseases. It also provides a continuous measure of HRQoL from sick to healthy people, allowing patients’ health status to be compared with that of the general population. The SF-8 also has only eight questions, which allows for quick evaluations and makes it suitable for large surveys. In addition, the SF-8 has national standards, and the health status of the target group can be compared based on the Japanese average (50 points).

The EQ-5D-5L is a scale for assessing HRQoL that is frequently used in medical settings. It is a five-dimensional questionnaire consisting of the following items: ‘degree of mobility,’ ‘personal management,’ ‘daily activities,’ ‘pain/discomfort,’ and ‘anxiety/stagnation.’ The EQ-5D-5L enables calculation of health-related quality of life that reflects the values of Japanese people. Quality-adjusted life years (QALYs), which can be calculated using the EQ-5D-5L, are a common measure of burden of disease and can be used to evaluate the cost-effectiveness of medical treatment. QALYs can be used as a common measure for many diseases, and multiple effects can be evaluated simultaneously, making the results easy to interpret and compare with other diseases. The QALYs calculated in this study can be used to compare the relationship between treatment during hospitalisation for COVID-19 and post-discharge QoL, and the QoL reductions caused by COVID-19 with those caused by other diseases. A previous study assessing the EQ-5D-5L before and after the onset of COVID-19 found a significant decrease in this score with the onset of COVID-19, suggesting that COVID-19 has a negative influence on the QoL and health burden on the economy. In a previous Iranian study that assessed HRQoL using EQ-5D-5L in 420 post-discharge patients with COVID-19, female gender, older age (>60 years), higher education, unemployment, Intensive Care Unit (ICU) admission and diabetes status showed a significant decrease in EQ-5D-5L values (p<0.05). As with these previous studies, the present study allows us to assess the extent of the decline in Japanese health-related quality of life after the onset of COVID-19 and the factors associated with the decline in this score. We can also consider the impact of national origin, race and region of onset on health-related quality of life through comparison with other previous studies.

The HADS is a self-administered questionnaire for patients that contains seven questions each about depression and anxiety, with a total of 14 questions to assess the results. Most clinical studies of COVID-19 using the HADS score have involved healthcare workers and the general population, and there is a paucity of studies that have assessed psychiatric symptoms such as anxiety and depression in patients with COVID-19. In a HADS-based study of 105 patients with COVID-19 in Italy, approximately 30% of the patients still showed morbidity at 1–3 months after COVID-19 improvement. In that study, HADS scores were significantly lower in patients with prolonged clinical symptoms such as apathy, dyspnoea and cognitive impairment as sequelae. The study also found no correlation between acute illness severity and anxiety and depression. Our study participants will be followed for up to 12 months, allowing a more objective assessment of the long-term evolution of psychiatric symptoms. In addition, our study will provide insights into the correlation between HADS score and sequelae and the severity at the acute phase in Japanese participants, and clarify the differences in HADS scores between races and regions by comparing the findings with those obtained in previous studies.

Previous studies have suggested that patients with a pandemic disease may have insomnia, and a sleep quality assessment by the Pittsburgh Sleep Quality Index in patients with COVID-19 in Wuhan also clearly showed sleep disturbances. This study revealed a significantly greater incidence of sleeping disorders among elderly patients and those with any chronic comorbidity. Notably, sleep quality in this study was significantly associated with the patients’ subjective perception of disease severity, not an objective clinical classification. Our study is also using the Pittsburgh Sleep Quality Index to assess insomnia in patients with COVID-19. The current study of inpatients can accurately assess the association between severity and comorbidity and sleep disorders, as well as the correlation with other physical and mental symptoms. Few studies have evaluated sleep disturbances in patients with COVID-19, and many studies have been conducted with healthcare professionals and the public. Thus, we believe that this study, which focused on patients with COVID-19, and evaluated their sleep disorders, will be valuable.

The mental health of workers is known to influence labour productivity in the workplace, and impaired mental health can lead to loss of workforce. In this social context, a situation called absenteeism, in which workers are absent from work due to a disease, is an objective fact and easy to comprehend, while the loss of labour force due to a worker’s reduced ability to perform work, called presenteeism, is more difficult to evaluate objectively. The latter is considered to be more severe loss of labour force and is a social problem. In response to this problem, the WHO has proposed the WHO-HPQ to provide an early assessment of workers’ mental health, and the Japanese version of this rating scale has already been created. From 2019 to 2020, although the COVID-19 pandemic severely limited economic activity worldwide, the extent to which the work performance of patients with COVID-19 was affected has not been assessed, and this study uses the WHO-HPQ to examine that aspect as well. This study will be the first investigation that allows for consideration of COVID-19 patients’ clinical information in relation to their work performance.

The current study assesses various aspects of the fear of the COVID-19 pandemic in Japanese patients with FCV-19S Japanese version, which consists of seven questions. The FCV-19S is in use worldwide, and previous studies with this scale have already been reported in many countries. Many studies have assessed the fear of the COVID-19 pandemic in the public. On the other hand, no studies have used the FCV-19S in patients with COVID-19, and the present study will provide an insight into the differences in fear scales between the public and patients. In addition, this study will evaluate the psychometric properties of the Japanese version of FCV-19S and reveal its associated factors in Japanese patients. The
findings will also allow assessment of the factors associated with fear scale scores, such as disease severity, specific symptoms, comorbidity and age groups.

At the end of the second part of the questionnaire, the subjects are also asked about their socioeconomic circumstances and relevant changes in the COVID-19 pandemic, including the situation of employment, income, social life and informal care informal care. This is because wealth status and other socioeconomic positions have been reported to affect the incidence and severity of COVID-19, while evidence is still scarce to understand the socioeconomic consequences among patients with COVID-19. This study includes patients with COVID-19 from remarkably diverse social backgrounds. Thus, the findings of the study will allow us to assess whether socioeconomic conditions may influence the severity and morbidity of COVID-19 in Japan as well, and to what extent the socioeconomic background of the patients may affect work performance, health-related quality of life and other parts of the patients’ life. Further, this study will contribute to fill the global evidence gap of the socioeconomic consequences among patients with COVID-19.

This is the first study in Japan to comprehensively investigate the clinical and socioeconomic information of patients with COVID-19 over a large scale and a long period of time. The results of this study are expected to provide a more accurate clinical picture of COVID-19, including its sequelae using a multidisciplinary approach. Several international rating scales are being used to assess the sequelae, which will allow objective considerations, as well as evaluations of differences between countries and regions and comparisons with previous studies. In particular, studies that have incorporated clinical aspects and socioeconomic consequences including informal care, work performance and other social life environments of patients with COVID-19 have not been reported in the past, and new insights are expected to be gained in this survey.

Author affiliations
1Department of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
2Department of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan
3Keio Global Research Institute, Keio University, Tokyo, Japan
4Department of Preventive Medicine and Public Health, Keio University School of Medicine, Tokyo, Japan
5Department of Health Policy and Management, Keio University School of Medicine, Tokyo, Japan
6Department of Neurology, Keio University School of Medicine, Tokyo, Japan
7Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
8Department of Otolaryngology, Keio University School of Medicine, Tokyo, Japan
9Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan
10Department of Dermatology, Keio University School of Medicine, Tokyo, Japan
11Department of Internal Medicine, Sano Kosei General Hospital, Tochigi, Japan
12Department of Internal Medicine, Keiyou Hospital, Kanagawa, Japan
13Department of Pulmonary Medicine, Kawasaki Municipal Hospital, Kanagawa, Japan
14Department of Internal Medicine, Nihon Koukan Hospital, Kanagawa, Japan
15Department of Rheumatology, National Hospital Organization Hokkaido Medical Center, Hokkaido, Japan
16Department of Respiratory Medicine, National Hospital Organisation Tokyo Medical Center, Tokyo, Japan
17Department of Respiratory Medicine, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
18Pulmonary Division, Department Internal Medicine, Saiseikai Utsunomiya Hospital, Tochigi, Japan
19Department of Medicine, Division of Allergy and Respiratory Medicine, Showa University Koto Toyou Hospital, Tokyo, Japan
20Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Saitama, Japan
21Department of Respiratory Medicine, Toyohashi Municipal Hospital, Aichi, Japan
22Department of Internal Medicine, Hino Municipal Hospital, Tokyo, Japan
23Department of Internal Medicine, Saitama Medical Center, Saitama, Japan
24Division of Pulmonary Medicine, Department of Internal Medicine, Tachikawa Hospital, Tokyo, Japan
25Respiratory Disease Center, Fukuijuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan
26Department of Pulmonary Medicine, Eiju General Hospital, Tokyo, Japan
27Department of Pulmonary Medicine, Saiseikai Central Hospital, Tokyo, Japan
28Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan
29Department of Respiratory Medicine, Ome Municipal General Hospital, Ome, Tokyo, Japan
30Department of Pulmonary Medicine, Kawasaki Municipal Ida Hospital, Kanagawa, Japan
31Department of Pulmonary Medicine, Saitama City Hospital, Saitama, Japan
32Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Osaka, Japan
33Department of General Internal Medicine, Fukuoka Tokushukai Hospital, Fukuoka, Japan
34Department of Internal Medicine, Division of Respiriology, Neurology, and Rheumatology, Kurume University School of Medicine, Fukuoka, Japan
35Department of Respiratory Medicine, International University of Health and Welfare Shioya Hospital, Tochigi, Japan
36Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan
37Department of Organoid Medicine, Keio University School of Medicine, Tokyo, Japan
38Biostatistics Unit, Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan
39Graduate School of Business Administration, Keio University, Tokyo, Japan
40Faculty of Economics, Keio University, Tokyo, Japan
41Department of Surgery, Keio University School of Medicine, Tokyo, Japan
42Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan

Acknowledgements We are thankful to all the patient and public reviewers who took the time to complete the survey and share their experiences with us.

Collaborators Japan COVID-19 Task Force.

Contributors Contributors H Namkoong, H Terai, K Masaki, M Ishii, and K Fukunaga conceived the study and participated in its design and coordination. H Namkoong, H Terai, K Masaki, M Ishii, and K Fukunaga participated in the design of the study and is responsible for the statistical analysis plan. K Nakagawara, H Namkoong, H Terai, K Masaki, T Tanakazaki, K Shimamoto, S Okamori, H Kabata, S Chubachi, M Ishii, Y Ishibashi, S Harada, T Fujita, D Ito, S Bun, H Tabuchi, S Kanazaki, E Shimizu, K Fukuda, J Yamagami, R Goto, Y Ikuta and K Fukunaga participated in the establishment of the study design. The study protocol was developed by all the authors of this manuscript. All authors read and approved the final version of the manuscript.

Funding JST CREST (JPMJCR20H2)

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods and analysis section for further details.

Patient consent for publication Consent obtained from parent(s)/guardian(s)
REFERENCES


